TickerFacts.

Company research / INMB

Inmune Bio, Inc. (INMB)

Build a valuation ↗↓ Download CSV

CIK 0001711754 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated NV
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Inmune Bio, Inc. reported revenue of $50.0K. Revenue grew 257.1% from the prior annual period.

Key ratios (year ended 2025-12-31)

n/m
Operating margin
n/m
Net margin
-195.3%
Return on year-end equity
257.1%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-21

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenuen/a$50.0K$14.0K$155.0K$374.0K$181.0K$11.0Kn/a$0$0
R&D Expensen/a$20.66M$33.17M$20.27M$17.07M$20.54M$5.92M$3.28M$3.35M$435.4K
Operating Income-$20.20M-$47.38M-$42.63M-$29.74M-$25.95M-$29.15M-$12.23M-$7.76M-$12.44M-$981.5K
Net Income-$18.42M-$45.93M-$42.08M-$30.01M-$27.30M-$30.34M-$12.10M-$7.68M-$12.44M-$831.5K
EPS (Diluted)n/a-$1.86-$2.11-$1.67-$1.52-$1.88n/an/an/an/a
Total Assets$26.84M$32.35M$39.56M$57.00M$81.80M$99.94M$40.66M$24.47M$17.36M$18.41M
Total Liabilities$6.48M$8.83M$7.46M$18.86M$21.69M$19.72M$1.90M$860.5K$823.8K$309.7K
Long-Term Debtn/an/a$15.00Mn/a$15.00M$15.00Mn/an/an/an/a
Shareholders' Equity$20.36M$23.52M$32.10M$37.34M$60.10M$80.22M$38.75M$23.61M$16.54M$18.10M
Cash & Equivalentsn/a$24.75M$20.92M$35.85M$52.15M$74.81M$21.97M$7.00M$186.2K$1.37M
Operating Cash Flow-$14.96M-$22.58M-$33.36M-$11.98M-$22.69M-$28.50M-$8.94M-$5.38M-$2.06M-$761.8K
Capital Expendituresn/a$1.04Mn/an/an/an/an/an/an/an/a
Free Cash Flown/a-$23.62Mn/an/an/an/an/an/an/an/a
Shares Outstanding27.65M26.59M22.28M17.95M17.95M17.84M13.48M10.77M8.72M8.32M
Weighted Average Diluted Sharesn/a24.76M19.94M17.98M17.93M16.13Mn/an/an/an/a
EPS (Basic)n/a-$1.86-$2.11-$1.67-$1.52-$1.88n/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView